346 related articles for article (PubMed ID: 19801945)
21. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.
Wilkinson J; Cope A; Gill J; Bourboulia D; Hayes P; Imami N; Kubo T; Marcelin A; Calvez V; Weiss R; Gazzard B; Boshoff C; Gotch F
J Virol; 2002 Mar; 76(6):2634-40. PubMed ID: 11861829
[TBL] [Abstract][Full Text] [Related]
22. Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS).
Polizzotto MN; Uldrick TS; Wyvill KM; Aleman K; Marshall V; Wang V; Whitby D; Pittaluga S; Jaffe ES; Millo C; Tosato G; Little RF; Steinberg SM; Sereti I; Yarchoan R
Clin Infect Dis; 2016 Mar; 62(6):730-738. PubMed ID: 26658701
[TBL] [Abstract][Full Text] [Related]
23. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.
Lacombe JM; Boue F; Grabar S; Viget N; Gazaignes S; Lascaux-Cametz AS; Pacanowski J; Partisani M; Launay O; Matheron S; Rosenthal E; Rouveix E; Tattevin P; de Truchis P; Costagliola D; Goedert JJ
AIDS; 2013 Feb; 27(4):635-43. PubMed ID: 23196937
[TBL] [Abstract][Full Text] [Related]
24. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome.
Chang CC; Dorasamy AA; Gosnell BI; Elliott JH; Spelman T; Omarjee S; Naranbhai V; Coovadia Y; Ndung'u T; Moosa MY; Lewin SR; French MA
AIDS; 2013 Aug; 27(13):2089-99. PubMed ID: 23525034
[TBL] [Abstract][Full Text] [Related]
25. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.
Uldrick TS; Wang V; O'Mahony D; Aleman K; Wyvill KM; Marshall V; Steinberg SM; Pittaluga S; Maric I; Whitby D; Tosato G; Little RF; Yarchoan R
Clin Infect Dis; 2010 Aug; 51(3):350-8. PubMed ID: 20583924
[TBL] [Abstract][Full Text] [Related]
26. Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial.
Volkow P; Chavez Galan L; Ramon-Luing L; Cruz-Velazquez J; Cornejo-Juarez P; Sada-Ovalle I; Perez-Padilla R; Islas-Muñoz B;
PLoS One; 2023; 18(5):e0280209. PubMed ID: 37195970
[TBL] [Abstract][Full Text] [Related]
27. Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma.
Tedeschi R; Bidoli E; Bortolin MT; Schioppa O; Vaccher E; De Paoli P
Oncotarget; 2015 Oct; 6(30):30334-42. PubMed ID: 26296972
[TBL] [Abstract][Full Text] [Related]
28. Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.
Kowalkowski MA; Kramer JR; Richardson PR; Suteria I; Chiao EY
Clin Infect Dis; 2015 May; 60(9):1405-14. PubMed ID: 25586682
[TBL] [Abstract][Full Text] [Related]
29. Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults.
Maskew M; MacPhail AP; Whitby D; Egger M; Fox MP
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):442-8. PubMed ID: 23614996
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for 'unmasking immune reconstitution inflammatory syndrome' presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients.
Valin N; Pacanowski J; Denoeud L; Lacombe K; Lalande V; Fonquernie L; Girard PM; Meynard JL
AIDS; 2010 Jun; 24(10):1519-25. PubMed ID: 20549841
[TBL] [Abstract][Full Text] [Related]
31. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.
Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord
Clin Infect Dis; 2016 Nov; 63(10):1373-1379. PubMed ID: 27535953
[TBL] [Abstract][Full Text] [Related]
32. A Fatal Case of Kaposi Sarcoma Immune Reconstitution Syndrome (KS-IRIS) Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS) or Multicentric Castleman Disease (MCD): A Case Report and Review.
Dumic I; Radovanovic M; Igandan O; Savic I; Nordstrom CW; Jevtic D; Subramanian A; Ramanan P
Am J Case Rep; 2020 Dec; 21():e926433. PubMed ID: 33268763
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
[TBL] [Abstract][Full Text] [Related]
35. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
[TBL] [Abstract][Full Text] [Related]
36. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome.
Leidner RS; Aboulafia DM
AIDS Patient Care STDS; 2005 Oct; 19(10):635-44. PubMed ID: 16232048
[TBL] [Abstract][Full Text] [Related]
37. Restricted Kaposi's sarcoma (KS) herpesvirus transcription in KS lesions from patients on successful antiretroviral therapy.
Dittmer DP
mBio; 2011; 2(6):e00138-11. PubMed ID: 22045987
[TBL] [Abstract][Full Text] [Related]
38. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.
Nguyen HQ; Magaret AS; Kitahata MM; Van Rompaey SE; Wald A; Casper C
AIDS; 2008 May; 22(8):937-45. PubMed ID: 18453853
[TBL] [Abstract][Full Text] [Related]
39. Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report.
Feller L; Anagnostopoulos C; Wood NH; Bouckaert M; Raubenheimer EJ; Lemmer J
J Periodontol; 2008 Feb; 79(2):362-8. PubMed ID: 18251652
[TBL] [Abstract][Full Text] [Related]
40. Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.
Guadalupe M; Pollock BH; Westbrook S; Redding S; Bullock D; Anstead G; Agan BK; Marconi VC; Barbieri S; Sankar V; Rebeles J; Flahive Y; Schoolfield J; Wang L; Lei X; Dow D; Yeh CK; Dang H; Infante AJ; Gao SJ
J Acquir Immune Defic Syndr; 2011 Jan; 56(1):83-90. PubMed ID: 21084997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
